These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30362916)

  • 21. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
    Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
    Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
    Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
    Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating national guidelines for prevention of cardiovascular disease in primary care.
    Marshall T
    J Eval Clin Pract; 2005 Oct; 11(5):452-61. PubMed ID: 16164586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.
    Heeg B; Damen J; Van Hout B
    Pharmacoeconomics; 2007; 25(12):1063-82. PubMed ID: 18047390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
    Saini SD; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Budget Impact Analysis of a Pharmacist-Provided Transition of Care Program.
    Ni W; Colayco D; Hashimoto J; Komoto K; Gowda C; Wearda B; McCombs J
    J Manag Care Spec Pharm; 2018 Feb; 24(2):90-96. PubMed ID: 29384028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis.
    Han X; Fox DS; Chu M; Dougherty JS; McCombs J
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1078-1085. PubMed ID: 30362921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.
    Weisman SM; Graham DY
    Arch Intern Med; 2002 Oct; 162(19):2197-202. PubMed ID: 12390062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
    Chambers M; Hutton J; Gladman J
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].
    Claes C; Mittendorf T; Grond M; von der Schulenburg JM
    Med Klin (Munich); 2008 Nov; 103(11):778-87. PubMed ID: 19165429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
    Hori M; Ikeda S; Okumura K; Matsuda S; Koretsune Y; Montouchet C; Watanabe-Fujinuma E; Evers T; Rossi B; Ruff L; Briere JB
    J Med Econ; 2016 Sep; 19(9):889-99. PubMed ID: 27112188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
    Wells PS; Prins MH; Beyer-Westendorf J; Lensing AWA; Haskell L; Levitan B; Laliberté F; Ashton V; Xiao Y; Lejeune D; Crivera C; Lefebvre P; Zhao Q; Yuan Z; Schein J; Prandoni P
    Chest; 2018 Dec; 154(6):1371-1378. PubMed ID: 30201406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.
    Sylvester KW; Cheng JW; Mehra MR
    Vasc Health Risk Manag; 2013; 9():245-54. PubMed ID: 23696706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.